USA flag logo/image

An Official Website of the United States Government

Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs)…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43AI098325
Solicitation Year:
2012
Solicitation Topic Code:
NIAID
Solicitation Number:
PA09-093
Small Business Information
NEOSTEM, INC.
420 LEXINGTON AVE SUITE 350 NEW YORK, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs) s
Agency: HHS
Contract: 1R43AI098325-01
Award Amount: $595,252.00
 

Abstract:

DESCRIPTION (provided by applicant): In the event of a nuclear accident or terrorist bomb, large numbers of casualties will have been exposed to acute high-dose radiation. Those exposed will have compromised immune systems such that the virulence and infectivity of biological agents is dramatically increased. A compromised immune system exacerbates the effects of infectious agents and may preclude use of vaccines. Death can occur within 1-6 weeks following radiation exposure due to overwhelming infectionor to massive bleeding. The primary cause of death from radiation injury is infection that is unrestrained due to the failure of the immune system. There is only one intervention that saves a fatally irradiated person - a rescue through stem cell transplantation. The cure rate for this treatment can be high, provided the treatment is delivered within 7-10 days following exposure to radiation. Our goal is to develop very small embryonic like stem cells (VSEL), which are autologous adult pluripotent stem cells, as a countermeasure to radiological and nuclear threat. The VSELs will be used to rescue the immune system of individuals suffering from the delayed effects of acute radiation syndrome (ARS). The cells are autologous and consequently when administered to a patient will not cause rejection or graft- versus host disease, a common cause of failure of allogeneic stem cell therapies. The cells are pluripotent and can be expanded and differentiated to all three germ cell lineages. In particular, VSELs can be differentiated to hemato/lymphopoietic lineage, and can rescue the immune system of mice exposed to lethal radiation. Furthermore, VSELs have been shown to repair damaged tissue in animal models of myocardial infarct and may also be effective in repairing other tissues including retina and pancreas. Consequently, VSELs might be an ideal cell therapy to regenerate the body's immune system and repair other tissues damaged by radiation exposure. Most importantly, VSELs are resistant to lethal irradiation, whichdestroys hematopoietic stem cells and most other stem cells in the body. Specifically, in mice exposed to lethal radiation, VSELs are alive in bone marrow and proliferate in response to the tissue damage caused by irradiation. Consequently, these cells represent a unique population of autologous PSCs that could be used to treat radiation exposure. Studies proposed in this grant will test whether irradiated VSELs, can rescue the immune system and prolong survival of irradiated mice. If successful, this finding would indicate that VSELs could be isolated from a person exposed to radiation and used to treat that same person. Furthermore, we will test whether human VSELs have the same curative effect as the murine VSELs and are able to reverse the loss of the hemato/lymphopoietic system resulting from whole body irradiation. Importantly, unlike the development of medicinal products which must undergo extensive preclinical testing before human trials, VSELs are autologous and may be more readily available for human testing once preclinical efficacy is established. PUBLIC HEALTH RELEVANCE: NeoStem's goal is to develop a human VSEL product that can be used to recover the lost immune system resulting from radiation exposure. The product, which is an autologous stem cell therapy derived from the patient, could be used to rescue patients that have been exposed to radiation due to nuclear accident or terrorist threat. The product could also be used to treat cancer patients who have undergone radiation therapy andwho consequently have compromised immune systems.

Principal Investigator:

Denis O. Rodgerson
510-521-7392
drodgerson@neostem.com

Business Contact:

Steven Krivicich
212-581-7013
Skrivicich@neostem.com
Small Business Information at Submission:

NEOSTEM, INC.
420 LEXINGTON AVE SUITE 350 NEW YORK, NY -

EIN/Tax ID: 122234356
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No